Inhibitory Effect of Orientin on Secretory Group IIA Phospholipase A2

Inflammation

Volumn 38, Issue 4, 2015, Pages 1631-1638

  Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

Author keywords

HUVEC; inflammation; orientin; sPLA2 IIA

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANXIOLYTIC AGENT; CYCLOOXYGENASE 2; FLAVONOID; ISOORIENTIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; ORIENTIN; PHOSPHOLIPASE A2; SECRETORY GROUP IIA PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GLUCOSIDE; PHOSPHOLIPASE A2 GROUP II;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INFLAMMATORY DISEASE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLAVONOIDS; GLUCOSIDES; GROUP II PHOSPHOLIPASES A2; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL;

EID: 84937250928     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0139-8     Document Type: Article

References (56)

1. Six, D.A., and E.A. Dennis. 2000. The expanding superfamily of phospholipase A(2) enzymes: Classification and characterization. Biochimica et Biophysica Acta 1488: 1–19.
2. Kudo, I., and M. Murakami. 2002. Phospholipase A2 enzymes. Prostaglandins & Other Lipid Mediators 68–69: 3–58.
3. Mitjavila, M.T., and J.J. Moreno. 2012. The effects of polyphenols on oxidative stress and the arachidonic acid cascade. Implications for the prevention/treatment of high prevalence diseases. Biochemical Pharmacology 84: 1113–1122.
4. Hara, S., I. Kudo, H.W. Chang, K. Matsuta, T. Miyamoto, and K. Inoue. 1989. Purification and characterization of extracellular phospholipase A2 from human synovial fluid in rheumatoid arthritis. Journal of Biochemistry 105: 395–399.
5. Seilhamer, J.J., W. Pruzanski, P. Vadas, et al. 1989. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. The Journal of Biological Chemistry 264: 5335–5338.
6. Menschikowski, M., A. Hagelgans, and G. Siegert. 2006. Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins & Other Lipid Mediators 79: 1–33.
7. Pruzanski, W., and P. Vadas. 1991. Phospholipase A2–a mediator between proximal and distal effectors of inflammation. Immunology Today 12: 143–146.
8. Waydhas, C., D. Nast-Kolb, K.H. Duswald, P. Lehnert, and L. Schweiberer. 1989. Prognostic value of serum phospholipase A in the multitraumatized patient. Klinische Wochenschrift 67: 203–206.
9. Nakano, T., O. Ohara, H. Teraoka, and H. Arita. 1990. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. The Journal of Biological Chemistry 265: 12745–12748.
10. Oka, S., and H. Arita. 1991. Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression. The Journal of Biological Chemistry 266: 9956–9960.
11. Crowl, R.M., T.J. Stoller, R.R. Conroy, and C.R. Stoner. 1991. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. The Journal of Biological Chemistry 266: 2647–2651.
12. Kumar, S., and A.K. Pandey. 2013. Chemistry and biological activities of flavonoids: An overview. TheScientificWorldJournal 2013: 162750.
13. Lindahl, M., and C. Tagesson. 1997. Flavonoids as phospholipase A2 inhibitors: Importance of their structure for selective inhibition of group II phospholipase A2. Inflammation 21: 347–356.
14. Hong, J., M. Bose, J. Ju, et al. 2004. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: Effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25: 1671–1679.
15. Lambert, J.D., J.E. Rice, J. Hong, Z. Hou, and C.S. Yang. 2005. Synthesis and biological activity of the tea catechin metabolites, M4 and M6 and their methoxy-derivatives. Bioorganic & Medicinal Chemistry Letters 15: 873–876.
16. Moreno, J.J. 2003. Effect of olive oil minor components on oxidative stress and arachidonic acid mobilization and metabolism by macrophages RAW 264.7. Free Radical Biology & Medicine 35: 1073–1081.
17. Vivancos, M., and J.J. Moreno. 2008. Effect of resveratrol, tyrosol and beta-sitosterol on oxidised low-density lipoprotein-stimulated oxidative stress, arachidonic acid release and prostaglandin E2 synthesis by RAW 264.7 macrophages. The British Journal of Nutrition 99: 1199–1207.
18. Dietrych-Szostak, D., and W. Oleszek. 1999. Effect of processing on the flavonoid content in buckwheat (Fagopyrum esculentum Moench) grain. Journal of Agricultural and Food Chemistry 47: 4384–4387.
19. Soulimani, R., C. Younos, S. Jarmouni, D. Bousta, R. Misslin, and F. Mortier. 1997. Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. Journal of Ethnopharmacology 57: 11–20.
20. Li, Y.L., S.C. Ma, Y.T. Yang, S.M. Ye, and P.P. But. 2002. Antiviral activities of flavonoids and organic acid from Trollius chinensis Bunge. Journal of Ethnopharmacology 79: 365–368.
21. Budzianowski, J., G. Pakulski, and J. Robak. 1991. Studies on antioxidative activity of some C-glycosylflavones. Polish Journal of Pharmacology and Pharmacy 43: 395–401.
22. Bae, J.S., W. Lee, J.O. Nam, J.E. Kim, S.W. Kim, and I.S. Kim. 2014. Transforming growth factor beta-induced protein promotes severe vascular inflammatory responses. American Journal of Respiratory and Critical Care Medicine 189: 779–786.
23. Ku, S.K., M.S. Han, M.Y. Lee, Y.M. Lee, and J.S. Bae. 2014. Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo. BMB Reports 47: 336–341.
24. Ku, S.K., and J.S. Bae. 2014. Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa. Archives of Pharmacal Research 37: 1454–1463.
25. Wang, H., H. Liao, M. Ochani, et al. 2004. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Medicine 10: 1216–1221.
26. Lee, W., S.K. Ku, and J.S. Bae. 2013. Emodin-6-O-beta-D-glucoside down-regulates endothelial protein C receptor shedding. Archives of Pharmacal Research 36: 1160–1165.
27. Menschikowski, M., A. Hagelgans, B. Heyne, et al. 2005. Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochimica et Biophysica Acta 1733: 157–171.
28. Bae, J.S., and A.R. Rezaie. 2010. Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms. Thrombosis Research 125: e9–e15.
29. Brenneis, C., T.J. Maier, R. Schmidt, et al. 2006. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB Journal 20: 1352–1360.
30. Shimoyama, Y., R. Sakamoto, T. Akaboshi, M. Tanaka, and K. Ohtsuki. 2001. Characterization of secretory type IIA phospholipase A2 (sPLA2-IIA) as a glycyrrhizin (GL)-binding protein and the GL-induced inhibition of the CK-II-mediated stimulation of sPLA2-IIA activity in vitro. Biological & Pharmaceutical Bulletin 24: 1004–1008.
31. Alaoui-El-Azher, M., Y. Wu, N. Havet, A. Israel, A. Lilienbaum, and L. Touqui. 2002. Arachidonic acid differentially affects basal and lipopolysaccharide-induced sPLA(2)-IIA expression in alveolar macrophages through NF-kappaB and PPAR-gamma-dependent pathways. Molecular Pharmacology 61: 786–794.
32. Kuwata, H., C. Fujimoto, E. Yoda, et al. 2007. A novel role of group VIB calcium-independent phospholipase A2 (iPLA2gamma) in the inducible expression of group IIA secretory PLA2 in rat fibroblastic cells. The Journal of Biological Chemistry 282: 20124–20132.
33. Flynn, J.T., and H. Hoff 3rd. 1995. Lipopolysaccharide induces time-dependent increases in prostaglandin H synthase-2 and cytosolic phospholipase A2 mRNA in cultured human microvessel-derived endothelial cells. Shock 4: 433–440.
34. Mallat, Z., G. Lambeau, and A. Tedgui. 2010. Lipoprotein-associated and secreted phospholipases A(2) in cardiovascular disease: Roles as biological effectors and biomarkers. Circulation 122: 2183–2200.
35. Goldblum, S.E., T.W. Brann, X. Ding, J. Pugin, and P.S. Tobias. 1994. Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro. The Journal of Clinical Investigation 93: 692–702.
36. Russell, J.A. 2006. Management of sepsis. The New England Journal of Medicine 355: 1699–1713.
37. Baluk, P., L.C. Yao, J. Feng, et al. 2009. TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. The Journal of Clinical Investigation 119: 2954–2964.
38. Mehta, D., and A.B., Malik. 2006. Signaling mechanisms regulating endothelial permeability. Physiological Reviews 86: 279–367.
39. Buras, J.A., B. Holzmann, and M. Sitkovsky. 2005. Animal models of sepsis: setting the stage. Nature Reviews Drug Discovery 4: 854–865.
40. Harris, S.G., J. Padilla, L. Koumas, D. Ray, and R.P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends in Immunology 23: 144–150.
41. Natarajan, G., M. Glibetic, V. Raykova, J.P. Ofenstein, R.L. Thomas, and J.V. Aranda. 2007. Nitric oxide and prostaglandin response to group B streptococcal infection in the lung. Annals of Clinical and Laboratory Science 37: 170–176.
42. Agard, M., S. Asakrah, and L.A. Morici. 2013. PGE(2) suppression of innate immunity during mucosal bacterial infection. Frontiers in Cellular and Infection Microbiology 3: 45.
43. Leslie, C.C. 1997. Properties and regulation of cytosolic phospholipase A2. The Journal of Biological Chemistry 272: 16709–16712.
44. Clark, J.D., A.R. Schievella, E.A. Nalefski, and L.L. Lin. 1995. Cytosolic phospholipase A2. Journal of Lipid Mediators and Cell Signalling 12: 83–117.
45. Sano, H., X. Zhu, A. Sano, et al. 2001. Extracellular signal-regulated kinase 1/2-mediated phosphorylation of cytosolic phospholipase A2 is essential for human eosinophil adhesion to fibronectin. The Journal of Immunology 166: 3515–3521.
46. Bosetti, F., and G.R. Weerasinghe. 2003. The expression of brain cyclooxygenase-2 is down-regulated in the cytosolic phospholipase A2 knockout mouse. Journal of Neurochemistry 87: 1471–1477.
47. Johann, S., E. Kampmann, B. Denecke, et al. 2008. Expression of enzymes involved in the prostanoid metabolism by cortical astrocytes after LPS-induced inflammation. Journal of Molecular Neuroscience 34: 177–185.
48. Martinez, J., and J.J. Moreno. 2001. Role of Ca2 + −independent phospholipase A2 on arachidonic acid release induced by reactive oxygen species. Archives of Biochemistry and Biophysics 392: 257–262.
49. Vivancos, M., and J.J. Moreno. 2002. Role of Ca(2+)-independent phospholipase A(2) and cyclooxygenase/lipoxygenase pathways in the nitric oxide production by murine macrophages stimulated by lipopolysaccharides. Nitric Oxide 6: 255–262.
50. Ferrer, R., and J.J. Moreno. 2010. Role of eicosanoids on intestinal epithelial homeostasis. Biochemical Pharmacology 80: 431–438.
51. Bradley, J.D., A.A. Dmitrienko, A.J. Kivitz, et al. 2005. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. The Journal of Rheumatology 32: 417–423.
52. Tanaka, K., T. Kato, K. Matsumoto, and T. Yoshida. 1993. Antiinflammatory action of thielocin A1 beta, a group II phospholipase A2 specific inhibitor, in rat carrageenan-induced pleurisy. Inflammation 17: 107–119.
53. Vadas, P., W. Pruzanski, J. Kim, and V. Fornasier. 1989. The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2. The American Journal of Pathology 134: 807–811.
54. Zeiher, B.G., J. Steingrub, P.F. Laterre, A. Dmitrienko, Y. Fukiishi, and E. Abraham. 2005. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Critical Care Medicine 33: 1741–1748.
55. Grass, D.S., R.H. Felkner, M.Y. Chiang, et al. 1996. Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. The Journal of Clinical Investigation 97: 2233–2241.
56. Beck, G., B.A. Yard, J. Schulte, et al. 2003. Secreted phospholipases A2 induce the expression of chemokines in microvascular endothelium. Biochemical and Biophysical Research Communications 300: 731–737.